| 0000-00-00 |
|
|
|
External link to document |
| 2019-06-07 |
66 |
Claim Construction Chart |
for the asserted claims of U.S. Patent No. 9,375,405 (“the ’405
patent”).
In order to narrow … e.g., ’405 patent, col.6 l.57- the ’405 patent,
…: See, patent at Fig. 1, 6:57-
e.g., ’405 patent, col.6 8…Evidence2 Intrinsic Evidence2
’405 patent, “from about 1% to about “from about 1% to about… composition may contain patent at Fig. 1, 6:57-
|
External link to document |
| 2019-06-28 |
68 |
Claim Construction Opening Brief |
s ANDA product”) infringe U.S.
Patent No. 9,375,405 (“the ’405 patent”).
Since that time, Accord…would literally infringe the
claims of the ’405 patent. The Court first rejected Amgen’s argument in its…2018 in the prior litigation involving the ’405 patent. See Amgen Inc. v.
Amneal Pharms. LLC et al., …specification or prosecution history of the ’405
patent, and no indication that a person of ordinary skill…2018
21 October 2019
1:18-cv-00956
835 Patent - Abbreviated New Drug Application(ANDA)
None |
External link to document |
| 2019-06-28 |
69 |
Claim Construction Opening Brief |
two disputed claim terms in U.S. Patent No.
9,375,405 (“the ’405 patent,” Rothman Decl. Ex. 1).1 For the… between the patent applicant
and the United States Patent and Trademark Office (“Patent Office”)). Phillips…Sensipar® tablets prior to the expiration of the ’405 patent.2 On
January 28, 2019, the Court entered a Scheduling…pharmaceutical compositions claimed in the ’405 Patent (“Williams Decl.”). The exhibits
referenced herein…STATEMENT OF FACTS
The claims of the ’405 patent are directed to pharmaceutical compositions comprising |
External link to document |
| 2019-06-28 |
70 |
Declaration |
Issue Date: March 8, 2005, US Patent 6,862,890 (of provisional
patent application 06/264,988 filed…U.S.
Patent No. 9,375,405 (“the ’405 patent,” Rothman Decl. Ex. 1.)
3. The ’405 patent claims…’405 Patent, which I understand may
be relevant to the Court’s interpretation of the ’405 Patent claims… In addition, I am an inventor of over 35 patents and patent applications
concerning pharmaceutical formulation…spheronization, which are noted in the ’405
patent. (’405 patent, Rothman Decl. Ex. 1, col. 9, ll. 42-45. |
External link to document |
| 2019-06-28 |
71 |
Declaration |
relates to a pharmaceutical composi-
6,001,884 A 12/1999 Nemeth et al. …; refers to compounds that bind to a calcium
6,001,884. Such calcium receptor-active compounds may be…exposure. There is also a need to 5,981,599, 6,001,884, 6,011,068, 6,031,003, 6,172,091,
improve the…(12) United States Patent (lo) Patent No.: US 9,375,… Plasma European Patent No. EP1663182, Opposition document, Patent
Parathyroid Hormone Levels |
External link to document |
